Shire PLC (NASDAQ:SHPG) has earned a consensus rating of “Hold” from the nineteen ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $217.27.
Several research firms recently issued reports on SHPG. Zacks Investment Research upgraded Shire from a “sell” rating to a “hold” rating in a research report on Tuesday, February 6th. Royal Bank of Canada set a $192.00 price target on Shire and gave the company a “buy” rating in a research note on Monday, February 5th. Bank of America increased their price target on Shire from $236.00 to $237.00 and gave the company a “buy” rating in a research note on Monday, February 5th. ValuEngine lowered Shire from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, BidaskClub lowered Shire from a “sell” rating to a “strong sell” rating in a research note on Friday, January 26th.
Shire (NASDAQ:SHPG) traded up $1.20 during trading hours on Friday, hitting $127.43. The company had a trading volume of 2,068,700 shares, compared to its average volume of 1,501,267. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. Shire has a 12-month low of $123.73 and a 12-month high of $192.15. The stock has a market capitalization of $38,342.93, a PE ratio of 24.56, a P/E/G ratio of 0.68 and a beta of 1.41.
Several large investors have recently bought and sold shares of the company. Commerzbank Aktiengesellschaft FI lifted its stake in shares of Shire by 22.1% in the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 2,073 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 375 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its stake in shares of Shire by 6.2% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 6,492 shares of the biopharmaceutical company’s stock valued at $1,073,000 after purchasing an additional 381 shares during the last quarter. Pitcairn Co. lifted its stake in shares of Shire by 26.5% in the 3rd quarter. Pitcairn Co. now owns 1,917 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 401 shares during the last quarter. Thompson Investment Management Inc. lifted its stake in shares of Shire by 5.2% in the 3rd quarter. Thompson Investment Management Inc. now owns 9,390 shares of the biopharmaceutical company’s stock valued at $1,438,000 after purchasing an additional 468 shares during the last quarter. Finally, Verition Fund Management LLC lifted its stake in shares of Shire by 18.9% in the 2nd quarter. Verition Fund Management LLC now owns 2,967 shares of the biopharmaceutical company’s stock valued at $490,000 after purchasing an additional 472 shares during the last quarter. 20.74% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Shire PLC (SHPG) Receives $217.27 Average Price Target from Analysts” was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.com-unik.info/2018/02/12/shire-plc-shpg-receives-217-27-average-price-target-from-analysts.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.